


[EBMT](#)
[Annual report](#)
[2024](#)



[ScienceEducationPatient Care & Advocacy](#)
[Our SocietyOur Mission, Vision & ValuesEBMT Membership 2024Organisational](#)
[Structure 2024Financial Highlights 2024EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Zinaida Perić
TCWP Chair
Croatia

Major achievements

During 2024, the TCWP finalised several important projects including **ERS/EBMT guidelines for lung GVHD** and **best practice recommendations for Non-ICANS neurological complications after CAR-T therapy**.

Several other important studies were also finalised in the form of publications, including the **study on management of complications after CAR-T therapy** as well as the **Survey on patient engagement in hematopoietic stem cell transplantation and cellular therapy**.

Furthermore, the TCWP conducted a successful **educational meeting focusing on complications post CAR-T**, in partnership with the PDWP, in Malaga in January 2025. The event followed the TCWP's effective format of patient case discussion and sharing of practical skills. Patient advocates, nurses and physicians all participated, with significant audience engagement in the activities and very positive feedback.

Finally, significant work was also done on the updating of **EBMT Registry data collection forms** to improve the quality and speed of TCWP studies in the future.

Principal research studies

[Daratumumab for PRCA after alloSCT](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Complications: non-infectious](#)

[Group](#)

[Transplant Complications Working Party \(TCWP\)](#)

[Type of treatment](#)

-

[Principal investigator](#)

[Nico Gagelmann](#)

[Outcomes of Allogeneic Hematopoietic Cell Transplantation from \$\leq 8/10\$ -HLA matched unrelated donor](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Transplant Complications Working Party \(TCWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Ivan Moiseev](#)

[Evaluating the Impact of ABO Compatibility on Allogeneic Stem Cell Transplantation](#)

[Outcomes](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Transplant Complications Working Party \(TCWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Mustafa Güven](#)

[How risky is a second allo? A retrospective analysis of treatment-related mortality in patients receiving allogeneic stem cell transplantation for the second time](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Transplant Complications Working Party \(TCWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Olaf Penack](#)

[Outcomes and risk factors for survival of lung transplantation after allogeneic HSCT](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

-

[Group](#)

[Transplant Complications Working Party \(TCWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Juan Montoro Gomez; Saskia Bos](#)

Key publications

2024

ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults

Group

Transplant Complications Working Party (TCWP)

Patient Advocacy Committee

1st listed author

Saskia Bos

Journal

Eur Respir J.

2024

PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation

Group

Transplant Complications Working Party (TCWP)

1st listed author

Olaf Penack

Journal

Blood Cancer J.

2024

ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?

Group

Transplant Complications Working Party (TCWP)

1st listed author

Olaf Penack

Journal

Leukemia.

2024

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study

Group

Transplant Complications Working Party (TCWP)

Paediatric Diseases Working Party (PDWP)

[1st listed author](#)

[Guillermo Ortí](#)

[Journal](#)

[Leukemia.](#)

[2024](#)

[How risky is a second allogeneic stem cell transplantation?](#)

[Group](#)

[Transplant Complications Working Party \(TCWP\)](#)

[1st listed author](#)

[Olaf Penack](#)

[Journal](#)


[Leukemia.](#)

[See the full list of the TCWP 2024 publications](#)




Indicators

Impact factor (Transplant Complications)



2022 2023 2024

Oral presentations	6	1	4
Poster presentations	5	9	4
Educational events	1	1	2



50th Annual Meeting of the EBMT



[Kingdom](#)

[Event](#)

***RESCHEDULED* Complications post CAR-T Cell Therapy in Paediatric and Adult Patients**

[Jan 16, 2025 - Jan 18, 2025 / Málaga, Spain](#)

[Discover more](#)

[VISIT THE TCWP WEBPAGE](#)